argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
851.29
-5.65 (-0.66%)
Aug 14, 2026, 4:00 PM EDT - Market closed
argenx SE Revenue
argenx SE had revenue of $1.54B in the quarter ending June 30, 2026, with 59.30% growth. This brings the company's revenue in the last twelve months to $5.33B, up 70.51% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth.
Revenue (ttm)
$5.33B
Revenue Growth
+70.51%
P/S Ratio
9.95
Revenue / Employee
$2,853,177
Employees
1,863
Market Cap
52.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | 27.09M | 416.32% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 15.53B |
| Vertex Pharmaceuticals | 12.59B |
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Moderna | 2.23B |
ARGX News
- 4 days ago - Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX - Business Wire
- 9 days ago - argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc. - GlobeNewsWire
- 10 days ago - ARGX Reinstated by Guggenheim -- Maintains Price Target at $1185 - GuruFocus
- 10 days ago - ARGX Looks 41.4% Undervalued on GF Value⢠- GuruFocus
- 10 days ago - Argenx resumed with a Buy at Guggenheim - TheFly
- 11 days ago - argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 - GlobeNewsWire
- 15 days ago - A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors - CNBC
- 16 days ago - IBB, REGN, ARGX, ALNY: Large Outflows Detected at ETF - Nasdaq